ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 1838 • ACR Convergence 2024

    M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases

    Michelle Downing1, Ling Zhang1, Aditee Desphpande1, Hong Zhang1, Ohad Tarcic2, Mira toister-achituv2, Alec Gross3, Gang Chen3 and Chia Chi Sun1, 1EMD Serono Research and Development Institute, Inc., Billerica, MA, 2Inter-lab Ltd, Merck KGaA, Yavne, Israel, 3EMD Serono Reserch and Development Institute, Inc, Billerica, MA

    Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…
  • Abstract Number: 2078 • ACR Convergence 2024

    Increased RAGE Expression in Myositis

    Madison King1, Rita Spathis2, Elizabeth Bagley1 and Melissa Morales3, 1Binghamton University, Johnson City, NY, 2Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, 3SUNY Binghamton, Johnson City, NY

    Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
  • Abstract Number: 2569 • ACR Convergence 2024

    A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders

    Hallie Carol1, Adam Mayer2, Jemy Varghese3, Zachary Martinez4, Caroline Diorio4, Paul Tsoukas5, Kate Kernan6 and Scott Canna7, 1Children's Hospital of Philadelphia, Philadelphia, 2University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 3Division of Pediatric Rheumatology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 4Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 5Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, 6Department of Critical Care Medicine, University of Pittsburgh School of Medicine, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, 7Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: High ferritin is an important and sensitive biomarker for the diverse and deadly group of cytokine storm syndromes grouped together under the term hemophagocytic…
  • Abstract Number: 0042 • ACR Convergence 2024

    Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model

    Eva Philippon1, Jan Piet van Hamburg1, Lisanne van Rooijen1, Gary Sims2, Conny Van der Laken3 and Sander Tas4, 1Amsterdam UMC, Amsterdam, Netherlands, 2Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 3Amsterdam UMC - location VUMC, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…
  • Abstract Number: 0266 • ACR Convergence 2024

    Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol

    Dansoa Tabi-Amponsah1, Lisa Stamp2, Anne Horne3, Jill Drake4, Sarah Stewart5, Gregory Gamble3, Keith Petrie1 and Nicola Dalbeth3, 1The University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Auckland University of Technology, Auckland, New Zealand

    Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
  • Abstract Number: 0567 • ACR Convergence 2024

    Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants

    Pankaj Sharma1, Fatemeh Navid1, Norman Watts1, Stephen Brooks2 and Robert Colbert2, 1National Institutes of Health, Bethesda, MD, 2NIH/NIAMS, Bethesda, MD

    Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
  • Abstract Number: 0880 • ACR Convergence 2024

    Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis

    Charles Besidonne1, Andrew Benest1, Kim Chisholm1, Jonathan Morris2, Lucy Donaldson3, Jeanette Woolard4 and David Bates1, 1University of Nottingham, Nottingham, United Kingdom, 2University of New South Wales, New South Wales, New South Wales, Australia, 3Versus Arthritis UK, Nottingham, United Kingdom, 4University of Nottingham, Nottingham, England, United Kingdom

    Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…
  • Abstract Number: 0996 • ACR Convergence 2024

    Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition

    Enelle Mevorach, Adi Tabib and Dror Mevorach, Hadassah-University Hospital, Jerusalem, Israel

    Background/Purpose: Following Pfizer-BioNTech BNT162b2 vaccine authorization, Israel initiated a nationwide COVID-19 vaccination campaign. The vaccine caused a higher incidence of myocarditis in young males. Here,…
  • Abstract Number: 1635 • ACR Convergence 2024

    Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management

    Matthias Froehlich1, Michael Gernert2, Marc Schmalzing3, Patrick-Pascal Strunz4, Hanna Labinsky5, Thorsten A. Bley6 and Konstanze V. Guggenberger6, 1Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, 2Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, 3University Hospital Wuerzburg, Würzburg, Germany, 4University hospital of Wuerzburg, Wuerzburg, Germany, 5University Hospital Würzburg, Wuerzburg, Germany, 6University Hospital Würzburg, Würzburg, Germany

    Background/Purpose: Imaging techniques such as magnetic resonance imaging (MRI) are a cornerstone for the diagnosis of giant cell arteritis (GCA). In the further course of…
  • Abstract Number: 1920 • ACR Convergence 2024

    Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis

    Jordan Hicks1, Daniel Shriner2, Ami Shah3, Maureen Mayes4, Ayo P. Doumatey2, Amy R. Bentley1, Robyn Domsic5, Thomas Medsger, Jr6, Paula Ramos7, Richard Silver8, Virginia Steen9, John Varga10, Vivien Hsu11, Lesley Ann Saketkoo12, Dinesh Khanna10, Elena Schiopu13, Jessica Gordon14, Lindsey Criswell15, Heather Gladue16, Chris Derk17, Elana Bernstein18, S. Louis Bridges14, Victoria Shanmugam19, Lorinda Chung20, Suzanne Kafaja21, Reem Jan22, Marcin Trojanowski23, Avram Goldberg24, Benjamin Korman25, James W. Thomas26, Elaine Remmers27, Adebowale Adeyemo2, Charles Rotimi2, Fredrick Wigley28, Francesco Boin29, Daniel Kastner30 and Pravitt Gourh31, 1National institute of Health, Bethesda, MD, 2Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 4UTHealth Houston Division of Rheumatology, Houston, TX, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, 7Medical University of South Carolina, Charleston, SC, 8Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 9Georgetown University School of Medicine, Washington, DC, 10University of Michigan, Ann Arbor, MI, 11Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, 12New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, 13Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, 14Division of Rheumatology, Weill Cornell Medical College, New York, NY, 15Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, 16Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 17Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 18Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 19NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, 20Stanford University, Woodside, CA, 21Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 22Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, 23Department of Rheumatology, Boston University School of Medicine, Boston, MA, 24NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, 25University of Rochester, Rochester, NY, 26NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 27Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 28Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 29Cedars-Sinai Medical Center, Los Angeles, CA, 30National Human Genome Research Institute, Bethesda, MD, 31National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD

    Background/Purpose: There are significant racial disparities in systemic sclerosis (SSc), with an increased disease burden and worse outcomes among African American (AA) individuals. Reasons for…
  • Abstract Number: 2079 • ACR Convergence 2024

    Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study

    Silvia Grazzini1, Angeles Galindo-Feria2, Edoardo Conticini1, Ingrid Lundberg3 and Maryam Dastmalchi4, 1Università di Siena, Siena, Italy, 2Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 3Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 4Karolinska University hospital, Stockholm, Sweden

    Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
  • Abstract Number: 2574 • ACR Convergence 2024

    Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children

    Mariia Pavlenko1, Ilaria Maccora2, Mekibib Altaye3, hermine brunner4, Alexandra Duell3, Megan Quinlan-Waters3, Alyssa Sproles1, Sherry Thornton5, Virginia Miraldi Utz3 and sheila Angeles-Han6, 1Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 2?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 5Cincinnati Children's Hospital, Cincinnati, 6Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Childhood chronic anterior uveitis (CAU) can be idiopathic (iCAU) or associated with Juvenile Idiopathic Arthritis (JIA-U). Ocular complications occur in 50% of affected children. …
  • Abstract Number: 0047 • ACR Convergence 2024

    Asthma Is Associated with Increased Serum IgA Antibodies to Citrullinated Peptide Antigenscompared to Healthy Controlsin Discovery and Validation Cohorts

    Drayton Rorah1, Linh Ngo2 and Scott Matson3, 1University of Kansas, Internal Medicine, Kansas City, KS, 2University of Kansas School of Medicine, Kansas City, 3University of Kansas, Kansas City, MO

    Background/Purpose: The connection between airway inflammation as seen in patients with asthma and rheumatoid arthritis (RA) has been suggested by previous epidemiologic studies. For instance,…
  • Abstract Number: 0271 • ACR Convergence 2024

    Intercritical Gout Represents a Systemic Inflammatory State

    Tanner Ourada1, Austin Wheeler2, Michael Duryee2, Bryant England2, Richard Reynolds3, James O'Dell2, Jeff Newcomb2, Michael Pillinger4, Robert Terkeltaub5, Ryan Ferguson6, Mary Brophy6, Tony Merriman7 and Ted Mikuls2, 1University of Nebraska-Medical Center: College of Medicine, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Alabama at Birmingham, Birmingham, AL, 4New York University Grossman School of Medicine, New York,, NY, 5Retired, San Diego, CA, 6Veterans Affairs, Boston, MA, 7University of Alabama at Birmingham, Homewood, AL

    Background/Purpose: The presence of systemic inflammation during gout flares is well characterized. While initial research suggests inflammation persists in intercritical gout, these reports have come…
  • Abstract Number: 0572 • ACR Convergence 2024

    Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects

    Patricia Remalante-Rayco1, Emmanuel Baja2, Zeynep Baskurt3, Tina Chim4, Robert Inman5, Leonila Dans6 and Nigil Haroon7, 1Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines, 3Department of Biostatistics, University Health Network, Toronto, Canada, 4Schroeder Arthritis Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, 5University Health Network, Toronto, ON, Canada, 6Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Recent evidence suggests lower response rates to tumor necrosis factor inhibitors (TNFi) among women with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is a paucity…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology